Skip to main content
Mijn bibliotheek
Shop
Nieuws Boeken Tijdschriften Toetsvragen Web-tv Video Audio
Tips voor Mijn BSL
Inloggen
Top
Quality of Life Research
Gepubliceerd in:

21-01-2019

Health-related quality of life in hepatitis C patients who achieve sustained virological response to direct-acting antivirals: a comparison with the general population

Auteurs: Regina Juanbeltz, Jesús Castilla, Iván Martínez-Baz, Aisling O’Leary, Maite Sarobe, Ramón San Miguel

Gepubliceerd in: Quality of Life Research | Uitgave 6/2019

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail
    Link delen
publish
Publiceer nu

Abstract

Purpose

To compare health-related quality of life (HRQoL) between hepatitis C patients who achieve sustained virological response (SVR) to direct-acting antivirals and a sex- and age-paired sample of the general population.

Methods

HRQoL was evaluated in patients recruited in Navarre, Spain, from May 2016 to April 2017 at baseline and after SVR, using the EQ-5D-5L questionnaire. Both results were compared to those of general population of the same sex and age obtained from the 2011/12 National Health Survey in Spain. Observed/expected (O/E) ratios for health dimensions and differences between O-E in EQ-5D utility and visual analogical scale (VAS) scores were calculated.

Results

206 patients were studied. Before treatment, patients had more problems than the general population in every domain of EQ-5D-5L, except in self-care dimension (O/E = 1.1). After SVR, patients continued having more limitation, especially for usual activities (O/E = 3.1), anxiety/depression (O/E = 2.8) and EQ-5D utility (− 0.086, p < 0.001); however, differences in VAS score between patients and general population disappeared (74.8 vs 76.5, p = 0.210). F0–F1 patients with SVR had minor differences with the general population in EQ-5D-5L dimensions, utility and VAS score. Although cirrhotic patients also reduced that difference, they still had worse HRQoL, especially in usual activities, self-care, EQ-5D utility (− 0.152, p < 0.001) and VAS score (− 8.5, p = 0.005).

Conclusions

HRQoL of chronic hepatitis C patients remains lower than that of the general population despite viral clearance, with primary problems in usual activities and anxiety/depression. Knowledge of these on-going problems despite cure serves to guide healthcare interventions and patient’s follow-up.
vorige artikel Using health-related quality of life to predict cardiovascular disease events
volgende artikel Modality transition on renal replacement therapy and quality of life of patients: a 10-year follow-up cohort study
Bijlagen
Alleen toegankelijk voor geautoriseerde gebruikers
Literatuur
1.
2.
Degasperi, E., Aghemo, A., & Colombo, M. (2017). Treatment of extrahepatic manifestations of hepatitis C virus. Clinics in Liver Disease, 21(3), 631–643.CrossRefPubMed
3.
Juanbeltz, R., Zozaya, J. M., Reparaz, J., Castilla, J., Sarobe, M. T., Uriz Otano, J. I., et al. (2017). Effectiveness of second-generation direct-acting antivirals in chronic hepatitis C. Anales del Sistema Sanitario de Navarra, 40(1), 57–66.PubMed
4.
Juanbeltz, R., Goñi Esarte, S., Uriz-Otano, J. I., Martinez Echeverria, A., Elizalde, I., Zozaya, J. M., et al. (2017). Safety of oral direct acting antiviral regimens for chronic hepatitis C in real life conditions. Postgraduate Medicine, 129(4), 476–483.CrossRefPubMed
5.
Kouris, G., Hydery, T., Greenwood, B. C., Lavitas, P., Price, M., Clements, K., et al. (2018). Effectiveness of Ledipasvir/Sofosbuvir and predictors of treatment failure in members with hepatitis C genotype 1 infection: A retrospective cohort study in a medicaid population. Journal of Managed Care and Specialty Pharmacy, 24(7), 591–597.CrossRefPubMed
6.
Honer Zu Siederdissen, C., Buggisch, P., Boker, K., Schott, E., Klinker, H., Pathil, A., et al. (2018). Treatment of hepatitis C genotype 1 infection in Germany: Effectiveness and safety of antiviral treatment in a real-world setting. United European Gastroenterology Journal, 6(2), 213–224.CrossRefPubMedPubMedCentral
7.
Hezode, C. (2018). Treatment of hepatitis C: Results in real life. Liver International, 38(Suppl 1), 21–27.CrossRefPubMed
8.
San Miguel, R., Gimeno-Ballester, V., Blazquez, A., & Mar, J. (2015). Cost-effectiveness analysis of sofosbuvir-based regimens for chronic hepatitis C. Gut, 64(8), 1277–1288.CrossRefPubMed
9.
Jakobsen, J. C., Nielsen, E. E., Koretz, R. L., & Gluud, C. (2018). Do direct acting antivirals cure chronic hepatitis C? British Medical Journal, 361, k1382.CrossRefPubMed
10.
Foster, G. R., Goldin, R. D., & Thomas, H. C. (1998). Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology, 27(1), 209–212.CrossRefPubMed
11.
Bjornsson, E., Verbaan, H., Oksanen, A., Fryden, A., Johansson, J., Friberg, S., et al. (2009). Health-related quality of life in patients with different stages of liver disease induced by hepatitis C. Scandinavian Journal of Gastroenterology, 44(7), 878–887.CrossRefPubMed
12.
Cordoba, J., Flavia, M., Jacas, C., Sauleda, S., Esteban, J. I., Vargas, V., et al. (2003). Quality of life and cognitive function in hepatitis C at different stages of liver disease. Journal of Hepatology, 39(2), 231–238.CrossRefPubMed
13.
Dusheiko, G. (2017). The impact of antiviral therapy for hepatitis C on the quality of life: A perspective. Liver International, 37(1), 7–12.CrossRefPubMed
14.
Juanbeltz, R., Martínez-Baz, I., San Miguel, R., Goñi-Esarte, S., Cabasés, J. M., & Castilla, J. (2018). Impact of successful treatment with direct-acting antiviral agents on health-related quality of life in chronic hepatitis C patients. PLoS ONE, 13(10), e0205277.CrossRefPubMedPubMedCentral
15.
San Miguel, R., del Villar, V., Perez, C., de Frutos, M., Mar, J., & Coma, M. J. (2010). Role of health-related quality of life measurements in the design of drug clinical trials. Farmacia Hospitalaria, 34(1), 16–22.CrossRefPubMed
16.
Miguel, R. S., Lopez-Gonzalez, A. M., Sanchez-Iriso, E., Mar, J., & Cabases, J. M. (2008). Measuring health-related quality of life in drug clinical trials: Is it given due importance? Pharmacy World and Science, 30(2), 154–160.CrossRefPubMed
17.
European Association for the Study of the Liver. (2018). EASL Recommendations on treatment of hepatitis C 2018. J Hepatol, 69(2), 461–511.CrossRef
18.
19.
Janssen, M. F., Pickard, A. S., Golicki, D., Gudex, C., Niewada, M., Scalone, L., et al. (2013). Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: A multi-country study. Quality of Life Research, 22(7), 1717–1727.CrossRefPubMed
20.
Devlin, N. J., Parkin, D., & Browne, J. (2010). Patient-reported outcome measures in the NHS: New methods for analysing and reporting EQ-5D data. Health Economics, 19(8), 886–905.CrossRefPubMed
21.
22.
Bedossa, P., & Poynard, T. (1996). An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology, 24(2), 289–293.CrossRefPubMed
23.
Rothman, K., & Boice, J. D. (1979). Epidemiologic analysis with a programmable calculator. Washington, DC: U.S. Dept. of Health, Education, and Welfare, Public Health Service, National Institutes of Health.
24.
25.
Manuel, D. G., Schultz, S. E., & Kopec, J. A. (2002). Measuring the health burden of chronic disease and injury using health adjusted life expectancy and the health utilities index. J Epidemiol Community Health, 56(11), 843–850.CrossRefPubMedPubMedCentral
26.
Fotos, N. V., Elefsiniotis, I., Patelarou, A., Giakoumidakis, K., Patelarou, E., Kouros, A., et al. (2018). Psychological disorders and quality of life among patients with chronic viral hepatitis: A single-center cross-sectional study with pair-matched healthy controls. Gastroenterology Nursing, 41(3), 206–218.CrossRefPubMed
27.
Hussain, K. B., Fontana, R. J., Moyer, C. A., Su, G. L., Sneed-Pee, N., & Lok, A. S. (2001). Comorbid illness is an important determinant of health-related quality of life in patients with chronic hepatitis C. American Journal of Gastroenterology, 96(9), 2737–2744.CrossRefPubMed
28.
Younossi, Z., Kallman, J., & Kincaid, J. (2007). The effects of HCV infection and management on health-related quality of life. Hepatology, 45(3), 806–816.CrossRefPubMed
29.
30.
Younossi, Z. M., Stepanova, M., Feld, J., Zeuzem, S., Sulkowski, M., Foster, G. R., et al. (2017). Sofosbuvir and velpatasvir combination improves patient-reported outcomes for patients with HCV infection, without or with compensated or decompensated cirrhosis. Clinical Gastroenterology and Hepatology, 15(3), 421–430.e6.CrossRefPubMed
31.
Marcellin, F., Roux, P., Protopopescu, C., Duracinsky, M., Spire, B., & Carrieri, M. P. (2017). Patient-reported outcomes with direct-acting antivirals for the treatment of chronic hepatitis C: current knowledge and outstanding issues. Expert Review of Gastroenterol and Hepatology, 11(3), 259–268.
32.
Younossi, Z. M., Stepanova, M., Henry, L., Nader, F., & Hunt, S. (2016). An in-depth analysis of patient-reported outcomes in patients with chronic hepatitis C treated with different anti-viral regimens. The American Journal of Gastroenterology, 111(6), 808–816.CrossRefPubMed
33.
Ragusa, R., Bertino, G., Bruno, A., Frazzetto, E., Cicciu, F., Giorgianni, G., et al. (2018). Evaluation of health status in patients with hepatitis c treated with and without interferon. Health and Quality of Life Outcomes, 16(1), 17.CrossRefPubMedPubMedCentral
34.
Thein, H. H., Krahn, M., Kaldor, J. M., & Dore, G. J. (2005). Estimation of utilities for chronic hepatitis C from SF-36 scores. The American Journal of Gastroenterology, 100(3), 643–651.CrossRefPubMed
35.
Chong, C. A., Gulamhussein, A., Heathcote, E. J., Lilly, L., Sherman, M., Naglie, G., et al. (2003). Health-state utilities and quality of life in hepatitis C patients. The American Journal of Gastroenterology, 98(3), 630–638.CrossRefPubMed
36.
Van Rooijen, E. M., Hotho, D., Agthoven, M., Van Der Kolk, A., Hansen, B. E., Knegt, R., & Uyl-De Groot, C. A. (2011). The cost and quality of life of hepatitis C in the Netherlands. Value in Health, 14, A394. [Conference abstract].CrossRef
37.
38.
Lens, S., Alvarado-Tapias, E., Mariño, Z., Londoño, M. C., Llop, E., Martinez, J., et al. (2017). Effects of all-oral anti-viral therapy on HVPG and systemic hemodynamics in patients with hepatitis C virus-associated cirrhosis. Gastroenterology, 153(5), 1273–1283.e1.CrossRefPubMed
39.
D’Ambrosio, R., Aghemo, A., Rumi, M. G., Ronchi, G., Donato, M. F., Paradis, V., et al. (2012). A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis. Hepatology, 56(2), 532–543.CrossRefPubMed
40.
Badia, X., Monserrat, S., Roset, M., & Herdman, M. (1999). Feasibility, validity and test-retest reliability of scaling methods for health states: the visual analogue scale and the time trade-off. Quality of Life Research, 8(4), 303–310.CrossRefPubMed
Metagegevens
Titel
Health-related quality of life in hepatitis C patients who achieve sustained virological response to direct-acting antivirals: a comparison with the general population
Auteurs
Regina Juanbeltz
Jesús Castilla
Iván Martínez-Baz
Aisling O’Leary
Maite Sarobe
Ramón San Miguel
Publicatiedatum
21-01-2019
Uitgeverij
Springer International Publishing
Gepubliceerd in
Quality of Life Research / Uitgave 6/2019
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-019-02111-1

Andere artikelen Uitgave 6/2019

Advancing the use of patient-reported outcomes in practice: understanding challenges, opportunities, and the potential of health information technology

Development and validation of the caregiver roles and responsibilities scale in cancer caregivers

  • Open Access

The combined polymorphisms of interleukin-6-174GG genotype and interleukin-10 ATA haplotype are associated with a poor quality of life in patients with chronic hepatitis C

Correction to: The impact of caregiver’s role preference on decisional conflicts and psychiatric distresses in decision making to help caregiver’s disclosure of terminal disease status

  • Correction

A pilot study on aesthetic treatments performed by qualified aesthetic practitioners: efficacy on health-related quality of life in breast cancer patients

  • Open Access

Multidimensionality of the PROMIS self-efficacy measure for managing chronic conditions